Global Tuberculin

Tuberculin Comprehensive Study by Type (PPD-S, PPD RT23, Others), Application (Human Use, Animal Use), Therapy (First-Line Therapy, Second-Line Therapy) Players and Region - Global Market Outlook to 2030

Tuberculin Market by XX Submarkets | Forecast Years 2024-2030 | CAGR: 5.45%  

Access Sample Report Make An Enquiry Before Purchase
  • Summary
  • Market Segments
  • Table of Content
  • List of Table & Figures
  • Players Profiled
What is Tuberculin?
Tuberculin also called Purified protein derivative is used for treatment of tuberculosis which is made of proteins. It is injected into the skin and if it swells after 48 hours the test is considered as positive. The test is conducted to recognise if the person is exposed to tuberculosis. Due to the increased awareness of tuberculosis and increased government initiatives the market is growing. Around 10,000 cases has been registered per year according to the TB facts

AttributesDetails
Study Period2018-2030
Base Year2023
UnitValue (USD Million)
Key Companies ProfiledSanofi Pasteur (France), Zoetis (United States), Par Sterile (United States), Japan BCG (Japan), Thermo Fisher (United States), CNBG (China), Chirana T. Injecta (Belarus), Arkray (Poland), Merck& Co. Inc.(United States) and Abbott (United States)
CAGR5.45%


The study covers a detailed analysis segmented by key business segments i.e. by type (PPD-S, PPD RT23 and Others) , by application (Human Use and Animal Use) and major geographies. Research Analyst at AMA predicts that Global Players will contribute to the maximum growth of Global Tuberculin market throughout the predicted period.

The competition is expected to become even more intense in the years to come due to the entry of several new players in the market. To help clients improve their revenue shares in the market, this research study provides an in-depth analysis of the market’s competitive landscape and offers information on the products offered by various leading companies. Additionally, this Tuberculin market report suggests strategies that Players can follow and highlights key areas they should focus on, in order to take maximum benefits of growth opportunities.

The report offers several leading Players, some of them are Sanofi Pasteur (France), Zoetis (United States), Par Sterile (United States), Japan BCG (Japan), Thermo Fisher (United States), CNBG (China), Chirana T. Injecta (Belarus), Arkray (Poland), Merck& Co. Inc.(United States) and Abbott (United States).

Market Overview:
In August 2023, The Project to Accelerate New Treatments for Tuberculosis collaboration announced the start of a phase 2b/c clinical trial, sponsored by the Bill & Melinda Gates Medical Research Institute (Gates MRI). The trial will evaluate whether novel regimens that combine registered products and new chemical entities have the potential to effectively treat drug-sensitive TB (DS-TB) and inform the development of a "pan-TB" regimen capable of treating all forms of active pulmonary TB.

In this market, the competition is high due to the availability of key players. They are focusing on the research and development which will help the players to innovate.

Influencing Trend:
Increasing Expenditure on Health Care in Developing Countries and Development of Advanced Technologies

Market Growth Drivers:
Spreading Awareness about the Tuberculin and Government Initiatives on the Drugs Related to Tuberculosis

Challenges:
Limited Availability of Players, Multi Drug Resistant Tuberculosis and Lack of Facilities of Laboratory

Restraints:
Stringent Government Regulations are Hampering the Market and High Costs Associated with the Product

Opportunities:
Rising Geriatric Population Globally

Key highlights of the Global Tuberculin market Study:
• CAGR of the market during the forecast period 2023-2030
• In-depth information on growth factors that will accelerate the Tuberculin market in next few years.
• Detailed Insights on futuristic trends and changing consumer behavior
• Forecast of the Global Tuberculin market size and its contribution to the parent market by type, application and by country.
• A broad view of customer demand
• Uncover market’s competitive landscape and in-depth information on various Players
• Comprehensive information about factors that will challenge the growth of Tuberculin Players

Transformation and Important Triggers:
Business transformation has taken hold across the broad corporate landscape due to the confluence of several important triggers, including:
• A tipping point in globalization
• A major slowdown in Western economies
• Significant shifts in technology and cost structure
• The challenges of regulatory compliance
• New forms of competition developing

Research Methodology:

The top-down and bottom-up approaches are used to estimate and validate the size of the Global Tuberculin market.
In order to reach an exhaustive list of functional and relevant players, various industry classification standards are closely followed such as NAICS, ICB, and SIC to penetrate deep into important geographies by players, and a thorough validation test is conducted to reach the most relevant players for survey in Tuberculin market.
In order to make a priority list sorting is done based on revenue generated based on the latest reporting, using paid databases such as Factiva, Bloomberg, etc.
Finally the questionnaire is set and specifically designed to address all the necessities for primary data collection after getting prior appointment> by targeting key target audience that includes Manufacturers, Raw Material Suppliers, Distributors and Traders, Research Organisations, Government Agencies and Organisations.
This helps us to gather the data for the players’ revenue, operating cycle and expense, profit along with product or service growth, etc.
Almost 70-80% of data is collected through primary medium and further validation is done through various secondary sources that include Regulators, World Bank, Association, Company Website, SEC filings, OTC BB, Annual reports, press releases, etc.

Report Objectives / Segmentation Covered

By Type
  • PPD-S
  • PPD RT23
  • Others
By Application
  • Human Use
  • Animal Use
By Therapy
  • First-Line Therapy
  • Second-Line Therapy

By Regions
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Asia Pacific
    • China
    • Japan
    • India
    • South Korea
    • Taiwan
    • Australia
    • Rest of Asia-Pacific
  • Europe
    • Germany
    • France
    • Italy
    • United Kingdom
    • Netherlands
    • Rest of Europe
  • MEA
    • Middle East
    • Africa
  • North America
    • United States
    • Canada
    • Mexico
  • 1. Market Overview
    • 1.1. Introduction
    • 1.2. Scope/Objective of the Study
      • 1.2.1. Research Objective
  • 2. Executive Summary
    • 2.1. Introduction
  • 3. Market Dynamics
    • 3.1. Introduction
    • 3.2. Market Drivers
      • 3.2.1. Spreading Awareness about the Tuberculin
      • 3.2.2. Government Initiatives on the Drugs Related to Tuberculosis
    • 3.3. Market Challenges
      • 3.3.1. Limited Availability of Players
      • 3.3.2. Multi Drug Resistant Tuberculosis
      • 3.3.3. Lack of Facilities of Laboratory
    • 3.4. Market Trends
      • 3.4.1. Increasing Expenditure on Health Care in Developing Countries
      • 3.4.2. Development of Advanced Technologies
  • 4. Market Factor Analysis
    • 4.1. Porters Five Forces
    • 4.2. Supply/Value Chain
    • 4.3. PESTEL analysis
    • 4.4. Market Entropy
    • 4.5. Patent/Trademark Analysis
  • 5. Global Tuberculin, by Type, Application, Therapy and Region (value) (2018-2023)
    • 5.1. Introduction
    • 5.2. Global Tuberculin (Value)
      • 5.2.1. Global Tuberculin by: Type (Value)
        • 5.2.1.1. PPD-S
        • 5.2.1.2. PPD RT23
        • 5.2.1.3. Others
      • 5.2.2. Global Tuberculin by: Application (Value)
        • 5.2.2.1. Human Use
        • 5.2.2.2. Animal Use
      • 5.2.3. Global Tuberculin by: Therapy (Value)
        • 5.2.3.1. First-Line Therapy
        • 5.2.3.2. Second-Line Therapy
      • 5.2.4. Global Tuberculin Region
        • 5.2.4.1. South America
          • 5.2.4.1.1. Brazil
          • 5.2.4.1.2. Argentina
          • 5.2.4.1.3. Rest of South America
        • 5.2.4.2. Asia Pacific
          • 5.2.4.2.1. China
          • 5.2.4.2.2. Japan
          • 5.2.4.2.3. India
          • 5.2.4.2.4. South Korea
          • 5.2.4.2.5. Taiwan
          • 5.2.4.2.6. Australia
          • 5.2.4.2.7. Rest of Asia-Pacific
        • 5.2.4.3. Europe
          • 5.2.4.3.1. Germany
          • 5.2.4.3.2. France
          • 5.2.4.3.3. Italy
          • 5.2.4.3.4. United Kingdom
          • 5.2.4.3.5. Netherlands
          • 5.2.4.3.6. Rest of Europe
        • 5.2.4.4. MEA
          • 5.2.4.4.1. Middle East
          • 5.2.4.4.2. Africa
        • 5.2.4.5. North America
          • 5.2.4.5.1. United States
          • 5.2.4.5.2. Canada
          • 5.2.4.5.3. Mexico
  • 6. Tuberculin: Manufacturers/Players Analysis
    • 6.1. Competitive Landscape
      • 6.1.1. Market Share Analysis
        • 6.1.1.1. Top 3
        • 6.1.1.2. Top 5
    • 6.2. Peer Group Analysis (2023)
    • 6.3. BCG Matrix
    • 6.4. Company Profile
      • 6.4.1. Sanofi Pasteur (France)
        • 6.4.1.1. Business Overview
        • 6.4.1.2. Products/Services Offerings
        • 6.4.1.3. Financial Analysis
        • 6.4.1.4. SWOT Analysis
      • 6.4.2. Zoetis (United States)
        • 6.4.2.1. Business Overview
        • 6.4.2.2. Products/Services Offerings
        • 6.4.2.3. Financial Analysis
        • 6.4.2.4. SWOT Analysis
      • 6.4.3. Par Sterile (United States)
        • 6.4.3.1. Business Overview
        • 6.4.3.2. Products/Services Offerings
        • 6.4.3.3. Financial Analysis
        • 6.4.3.4. SWOT Analysis
      • 6.4.4. Japan BCG (Japan)
        • 6.4.4.1. Business Overview
        • 6.4.4.2. Products/Services Offerings
        • 6.4.4.3. Financial Analysis
        • 6.4.4.4. SWOT Analysis
      • 6.4.5. Thermo Fisher (United States)
        • 6.4.5.1. Business Overview
        • 6.4.5.2. Products/Services Offerings
        • 6.4.5.3. Financial Analysis
        • 6.4.5.4. SWOT Analysis
      • 6.4.6. CNBG (China)
        • 6.4.6.1. Business Overview
        • 6.4.6.2. Products/Services Offerings
        • 6.4.6.3. Financial Analysis
        • 6.4.6.4. SWOT Analysis
      • 6.4.7. Chirana T. Injecta (Belarus)
        • 6.4.7.1. Business Overview
        • 6.4.7.2. Products/Services Offerings
        • 6.4.7.3. Financial Analysis
        • 6.4.7.4. SWOT Analysis
      • 6.4.8. Arkray (Poland)
        • 6.4.8.1. Business Overview
        • 6.4.8.2. Products/Services Offerings
        • 6.4.8.3. Financial Analysis
        • 6.4.8.4. SWOT Analysis
      • 6.4.9. Merck& Co. Inc.(United States)
        • 6.4.9.1. Business Overview
        • 6.4.9.2. Products/Services Offerings
        • 6.4.9.3. Financial Analysis
        • 6.4.9.4. SWOT Analysis
      • 6.4.10. Abbott (United States)
        • 6.4.10.1. Business Overview
        • 6.4.10.2. Products/Services Offerings
        • 6.4.10.3. Financial Analysis
        • 6.4.10.4. SWOT Analysis
  • 7. Global Tuberculin Sale, by Type, Application, Therapy and Region (value) (2025-2030)
    • 7.1. Introduction
    • 7.2. Global Tuberculin (Value)
      • 7.2.1. Global Tuberculin by: Type (Value)
        • 7.2.1.1. PPD-S
        • 7.2.1.2. PPD RT23
        • 7.2.1.3. Others
      • 7.2.2. Global Tuberculin by: Application (Value)
        • 7.2.2.1. Human Use
        • 7.2.2.2. Animal Use
      • 7.2.3. Global Tuberculin by: Therapy (Value)
        • 7.2.3.1. First-Line Therapy
        • 7.2.3.2. Second-Line Therapy
      • 7.2.4. Global Tuberculin Region
        • 7.2.4.1. South America
          • 7.2.4.1.1. Brazil
          • 7.2.4.1.2. Argentina
          • 7.2.4.1.3. Rest of South America
        • 7.2.4.2. Asia Pacific
          • 7.2.4.2.1. China
          • 7.2.4.2.2. Japan
          • 7.2.4.2.3. India
          • 7.2.4.2.4. South Korea
          • 7.2.4.2.5. Taiwan
          • 7.2.4.2.6. Australia
          • 7.2.4.2.7. Rest of Asia-Pacific
        • 7.2.4.3. Europe
          • 7.2.4.3.1. Germany
          • 7.2.4.3.2. France
          • 7.2.4.3.3. Italy
          • 7.2.4.3.4. United Kingdom
          • 7.2.4.3.5. Netherlands
          • 7.2.4.3.6. Rest of Europe
        • 7.2.4.4. MEA
          • 7.2.4.4.1. Middle East
          • 7.2.4.4.2. Africa
        • 7.2.4.5. North America
          • 7.2.4.5.1. United States
          • 7.2.4.5.2. Canada
          • 7.2.4.5.3. Mexico
  • 8. Appendix
    • 8.1. Acronyms
  • 9. Methodology and Data Source
    • 9.1. Methodology/Research Approach
      • 9.1.1. Research Programs/Design
      • 9.1.2. Market Size Estimation
      • 9.1.3. Market Breakdown and Data Triangulation
    • 9.2. Data Source
      • 9.2.1. Secondary Sources
      • 9.2.2. Primary Sources
    • 9.3. Disclaimer
List of Tables
  • Table 1. Tuberculin: by Type(USD Million)
  • Table 2. Tuberculin PPD-S , by Region USD Million (2018-2023)
  • Table 3. Tuberculin PPD RT23 , by Region USD Million (2018-2023)
  • Table 4. Tuberculin Others , by Region USD Million (2018-2023)
  • Table 5. Tuberculin: by Application(USD Million)
  • Table 6. Tuberculin Human Use , by Region USD Million (2018-2023)
  • Table 7. Tuberculin Animal Use , by Region USD Million (2018-2023)
  • Table 8. Tuberculin: by Therapy(USD Million)
  • Table 9. Tuberculin First-Line Therapy , by Region USD Million (2018-2023)
  • Table 10. Tuberculin Second-Line Therapy , by Region USD Million (2018-2023)
  • Table 11. South America Tuberculin, by Country USD Million (2018-2023)
  • Table 12. South America Tuberculin, by Type USD Million (2018-2023)
  • Table 13. South America Tuberculin, by Application USD Million (2018-2023)
  • Table 14. South America Tuberculin, by Therapy USD Million (2018-2023)
  • Table 15. Brazil Tuberculin, by Type USD Million (2018-2023)
  • Table 16. Brazil Tuberculin, by Application USD Million (2018-2023)
  • Table 17. Brazil Tuberculin, by Therapy USD Million (2018-2023)
  • Table 18. Argentina Tuberculin, by Type USD Million (2018-2023)
  • Table 19. Argentina Tuberculin, by Application USD Million (2018-2023)
  • Table 20. Argentina Tuberculin, by Therapy USD Million (2018-2023)
  • Table 21. Rest of South America Tuberculin, by Type USD Million (2018-2023)
  • Table 22. Rest of South America Tuberculin, by Application USD Million (2018-2023)
  • Table 23. Rest of South America Tuberculin, by Therapy USD Million (2018-2023)
  • Table 24. Asia Pacific Tuberculin, by Country USD Million (2018-2023)
  • Table 25. Asia Pacific Tuberculin, by Type USD Million (2018-2023)
  • Table 26. Asia Pacific Tuberculin, by Application USD Million (2018-2023)
  • Table 27. Asia Pacific Tuberculin, by Therapy USD Million (2018-2023)
  • Table 28. China Tuberculin, by Type USD Million (2018-2023)
  • Table 29. China Tuberculin, by Application USD Million (2018-2023)
  • Table 30. China Tuberculin, by Therapy USD Million (2018-2023)
  • Table 31. Japan Tuberculin, by Type USD Million (2018-2023)
  • Table 32. Japan Tuberculin, by Application USD Million (2018-2023)
  • Table 33. Japan Tuberculin, by Therapy USD Million (2018-2023)
  • Table 34. India Tuberculin, by Type USD Million (2018-2023)
  • Table 35. India Tuberculin, by Application USD Million (2018-2023)
  • Table 36. India Tuberculin, by Therapy USD Million (2018-2023)
  • Table 37. South Korea Tuberculin, by Type USD Million (2018-2023)
  • Table 38. South Korea Tuberculin, by Application USD Million (2018-2023)
  • Table 39. South Korea Tuberculin, by Therapy USD Million (2018-2023)
  • Table 40. Taiwan Tuberculin, by Type USD Million (2018-2023)
  • Table 41. Taiwan Tuberculin, by Application USD Million (2018-2023)
  • Table 42. Taiwan Tuberculin, by Therapy USD Million (2018-2023)
  • Table 43. Australia Tuberculin, by Type USD Million (2018-2023)
  • Table 44. Australia Tuberculin, by Application USD Million (2018-2023)
  • Table 45. Australia Tuberculin, by Therapy USD Million (2018-2023)
  • Table 46. Rest of Asia-Pacific Tuberculin, by Type USD Million (2018-2023)
  • Table 47. Rest of Asia-Pacific Tuberculin, by Application USD Million (2018-2023)
  • Table 48. Rest of Asia-Pacific Tuberculin, by Therapy USD Million (2018-2023)
  • Table 49. Europe Tuberculin, by Country USD Million (2018-2023)
  • Table 50. Europe Tuberculin, by Type USD Million (2018-2023)
  • Table 51. Europe Tuberculin, by Application USD Million (2018-2023)
  • Table 52. Europe Tuberculin, by Therapy USD Million (2018-2023)
  • Table 53. Germany Tuberculin, by Type USD Million (2018-2023)
  • Table 54. Germany Tuberculin, by Application USD Million (2018-2023)
  • Table 55. Germany Tuberculin, by Therapy USD Million (2018-2023)
  • Table 56. France Tuberculin, by Type USD Million (2018-2023)
  • Table 57. France Tuberculin, by Application USD Million (2018-2023)
  • Table 58. France Tuberculin, by Therapy USD Million (2018-2023)
  • Table 59. Italy Tuberculin, by Type USD Million (2018-2023)
  • Table 60. Italy Tuberculin, by Application USD Million (2018-2023)
  • Table 61. Italy Tuberculin, by Therapy USD Million (2018-2023)
  • Table 62. United Kingdom Tuberculin, by Type USD Million (2018-2023)
  • Table 63. United Kingdom Tuberculin, by Application USD Million (2018-2023)
  • Table 64. United Kingdom Tuberculin, by Therapy USD Million (2018-2023)
  • Table 65. Netherlands Tuberculin, by Type USD Million (2018-2023)
  • Table 66. Netherlands Tuberculin, by Application USD Million (2018-2023)
  • Table 67. Netherlands Tuberculin, by Therapy USD Million (2018-2023)
  • Table 68. Rest of Europe Tuberculin, by Type USD Million (2018-2023)
  • Table 69. Rest of Europe Tuberculin, by Application USD Million (2018-2023)
  • Table 70. Rest of Europe Tuberculin, by Therapy USD Million (2018-2023)
  • Table 71. MEA Tuberculin, by Country USD Million (2018-2023)
  • Table 72. MEA Tuberculin, by Type USD Million (2018-2023)
  • Table 73. MEA Tuberculin, by Application USD Million (2018-2023)
  • Table 74. MEA Tuberculin, by Therapy USD Million (2018-2023)
  • Table 75. Middle East Tuberculin, by Type USD Million (2018-2023)
  • Table 76. Middle East Tuberculin, by Application USD Million (2018-2023)
  • Table 77. Middle East Tuberculin, by Therapy USD Million (2018-2023)
  • Table 78. Africa Tuberculin, by Type USD Million (2018-2023)
  • Table 79. Africa Tuberculin, by Application USD Million (2018-2023)
  • Table 80. Africa Tuberculin, by Therapy USD Million (2018-2023)
  • Table 81. North America Tuberculin, by Country USD Million (2018-2023)
  • Table 82. North America Tuberculin, by Type USD Million (2018-2023)
  • Table 83. North America Tuberculin, by Application USD Million (2018-2023)
  • Table 84. North America Tuberculin, by Therapy USD Million (2018-2023)
  • Table 85. United States Tuberculin, by Type USD Million (2018-2023)
  • Table 86. United States Tuberculin, by Application USD Million (2018-2023)
  • Table 87. United States Tuberculin, by Therapy USD Million (2018-2023)
  • Table 88. Canada Tuberculin, by Type USD Million (2018-2023)
  • Table 89. Canada Tuberculin, by Application USD Million (2018-2023)
  • Table 90. Canada Tuberculin, by Therapy USD Million (2018-2023)
  • Table 91. Mexico Tuberculin, by Type USD Million (2018-2023)
  • Table 92. Mexico Tuberculin, by Application USD Million (2018-2023)
  • Table 93. Mexico Tuberculin, by Therapy USD Million (2018-2023)
  • Table 94. Company Basic Information, Sales Area and Its Competitors
  • Table 95. Company Basic Information, Sales Area and Its Competitors
  • Table 96. Company Basic Information, Sales Area and Its Competitors
  • Table 97. Company Basic Information, Sales Area and Its Competitors
  • Table 98. Company Basic Information, Sales Area and Its Competitors
  • Table 99. Company Basic Information, Sales Area and Its Competitors
  • Table 100. Company Basic Information, Sales Area and Its Competitors
  • Table 101. Company Basic Information, Sales Area and Its Competitors
  • Table 102. Company Basic Information, Sales Area and Its Competitors
  • Table 103. Company Basic Information, Sales Area and Its Competitors
  • Table 104. Tuberculin: by Type(USD Million)
  • Table 105. Tuberculin PPD-S , by Region USD Million (2025-2030)
  • Table 106. Tuberculin PPD RT23 , by Region USD Million (2025-2030)
  • Table 107. Tuberculin Others , by Region USD Million (2025-2030)
  • Table 108. Tuberculin: by Application(USD Million)
  • Table 109. Tuberculin Human Use , by Region USD Million (2025-2030)
  • Table 110. Tuberculin Animal Use , by Region USD Million (2025-2030)
  • Table 111. Tuberculin: by Therapy(USD Million)
  • Table 112. Tuberculin First-Line Therapy , by Region USD Million (2025-2030)
  • Table 113. Tuberculin Second-Line Therapy , by Region USD Million (2025-2030)
  • Table 114. South America Tuberculin, by Country USD Million (2025-2030)
  • Table 115. South America Tuberculin, by Type USD Million (2025-2030)
  • Table 116. South America Tuberculin, by Application USD Million (2025-2030)
  • Table 117. South America Tuberculin, by Therapy USD Million (2025-2030)
  • Table 118. Brazil Tuberculin, by Type USD Million (2025-2030)
  • Table 119. Brazil Tuberculin, by Application USD Million (2025-2030)
  • Table 120. Brazil Tuberculin, by Therapy USD Million (2025-2030)
  • Table 121. Argentina Tuberculin, by Type USD Million (2025-2030)
  • Table 122. Argentina Tuberculin, by Application USD Million (2025-2030)
  • Table 123. Argentina Tuberculin, by Therapy USD Million (2025-2030)
  • Table 124. Rest of South America Tuberculin, by Type USD Million (2025-2030)
  • Table 125. Rest of South America Tuberculin, by Application USD Million (2025-2030)
  • Table 126. Rest of South America Tuberculin, by Therapy USD Million (2025-2030)
  • Table 127. Asia Pacific Tuberculin, by Country USD Million (2025-2030)
  • Table 128. Asia Pacific Tuberculin, by Type USD Million (2025-2030)
  • Table 129. Asia Pacific Tuberculin, by Application USD Million (2025-2030)
  • Table 130. Asia Pacific Tuberculin, by Therapy USD Million (2025-2030)
  • Table 131. China Tuberculin, by Type USD Million (2025-2030)
  • Table 132. China Tuberculin, by Application USD Million (2025-2030)
  • Table 133. China Tuberculin, by Therapy USD Million (2025-2030)
  • Table 134. Japan Tuberculin, by Type USD Million (2025-2030)
  • Table 135. Japan Tuberculin, by Application USD Million (2025-2030)
  • Table 136. Japan Tuberculin, by Therapy USD Million (2025-2030)
  • Table 137. India Tuberculin, by Type USD Million (2025-2030)
  • Table 138. India Tuberculin, by Application USD Million (2025-2030)
  • Table 139. India Tuberculin, by Therapy USD Million (2025-2030)
  • Table 140. South Korea Tuberculin, by Type USD Million (2025-2030)
  • Table 141. South Korea Tuberculin, by Application USD Million (2025-2030)
  • Table 142. South Korea Tuberculin, by Therapy USD Million (2025-2030)
  • Table 143. Taiwan Tuberculin, by Type USD Million (2025-2030)
  • Table 144. Taiwan Tuberculin, by Application USD Million (2025-2030)
  • Table 145. Taiwan Tuberculin, by Therapy USD Million (2025-2030)
  • Table 146. Australia Tuberculin, by Type USD Million (2025-2030)
  • Table 147. Australia Tuberculin, by Application USD Million (2025-2030)
  • Table 148. Australia Tuberculin, by Therapy USD Million (2025-2030)
  • Table 149. Rest of Asia-Pacific Tuberculin, by Type USD Million (2025-2030)
  • Table 150. Rest of Asia-Pacific Tuberculin, by Application USD Million (2025-2030)
  • Table 151. Rest of Asia-Pacific Tuberculin, by Therapy USD Million (2025-2030)
  • Table 152. Europe Tuberculin, by Country USD Million (2025-2030)
  • Table 153. Europe Tuberculin, by Type USD Million (2025-2030)
  • Table 154. Europe Tuberculin, by Application USD Million (2025-2030)
  • Table 155. Europe Tuberculin, by Therapy USD Million (2025-2030)
  • Table 156. Germany Tuberculin, by Type USD Million (2025-2030)
  • Table 157. Germany Tuberculin, by Application USD Million (2025-2030)
  • Table 158. Germany Tuberculin, by Therapy USD Million (2025-2030)
  • Table 159. France Tuberculin, by Type USD Million (2025-2030)
  • Table 160. France Tuberculin, by Application USD Million (2025-2030)
  • Table 161. France Tuberculin, by Therapy USD Million (2025-2030)
  • Table 162. Italy Tuberculin, by Type USD Million (2025-2030)
  • Table 163. Italy Tuberculin, by Application USD Million (2025-2030)
  • Table 164. Italy Tuberculin, by Therapy USD Million (2025-2030)
  • Table 165. United Kingdom Tuberculin, by Type USD Million (2025-2030)
  • Table 166. United Kingdom Tuberculin, by Application USD Million (2025-2030)
  • Table 167. United Kingdom Tuberculin, by Therapy USD Million (2025-2030)
  • Table 168. Netherlands Tuberculin, by Type USD Million (2025-2030)
  • Table 169. Netherlands Tuberculin, by Application USD Million (2025-2030)
  • Table 170. Netherlands Tuberculin, by Therapy USD Million (2025-2030)
  • Table 171. Rest of Europe Tuberculin, by Type USD Million (2025-2030)
  • Table 172. Rest of Europe Tuberculin, by Application USD Million (2025-2030)
  • Table 173. Rest of Europe Tuberculin, by Therapy USD Million (2025-2030)
  • Table 174. MEA Tuberculin, by Country USD Million (2025-2030)
  • Table 175. MEA Tuberculin, by Type USD Million (2025-2030)
  • Table 176. MEA Tuberculin, by Application USD Million (2025-2030)
  • Table 177. MEA Tuberculin, by Therapy USD Million (2025-2030)
  • Table 178. Middle East Tuberculin, by Type USD Million (2025-2030)
  • Table 179. Middle East Tuberculin, by Application USD Million (2025-2030)
  • Table 180. Middle East Tuberculin, by Therapy USD Million (2025-2030)
  • Table 181. Africa Tuberculin, by Type USD Million (2025-2030)
  • Table 182. Africa Tuberculin, by Application USD Million (2025-2030)
  • Table 183. Africa Tuberculin, by Therapy USD Million (2025-2030)
  • Table 184. North America Tuberculin, by Country USD Million (2025-2030)
  • Table 185. North America Tuberculin, by Type USD Million (2025-2030)
  • Table 186. North America Tuberculin, by Application USD Million (2025-2030)
  • Table 187. North America Tuberculin, by Therapy USD Million (2025-2030)
  • Table 188. United States Tuberculin, by Type USD Million (2025-2030)
  • Table 189. United States Tuberculin, by Application USD Million (2025-2030)
  • Table 190. United States Tuberculin, by Therapy USD Million (2025-2030)
  • Table 191. Canada Tuberculin, by Type USD Million (2025-2030)
  • Table 192. Canada Tuberculin, by Application USD Million (2025-2030)
  • Table 193. Canada Tuberculin, by Therapy USD Million (2025-2030)
  • Table 194. Mexico Tuberculin, by Type USD Million (2025-2030)
  • Table 195. Mexico Tuberculin, by Application USD Million (2025-2030)
  • Table 196. Mexico Tuberculin, by Therapy USD Million (2025-2030)
  • Table 197. Research Programs/Design for This Report
  • Table 198. Key Data Information from Secondary Sources
  • Table 199. Key Data Information from Primary Sources
List of Figures
  • Figure 1. Porters Five Forces
  • Figure 2. Supply/Value Chain
  • Figure 3. PESTEL analysis
  • Figure 4. Global Tuberculin: by Type USD Million (2018-2023)
  • Figure 5. Global Tuberculin: by Application USD Million (2018-2023)
  • Figure 6. Global Tuberculin: by Therapy USD Million (2018-2023)
  • Figure 7. South America Tuberculin Share (%), by Country
  • Figure 8. Asia Pacific Tuberculin Share (%), by Country
  • Figure 9. Europe Tuberculin Share (%), by Country
  • Figure 10. MEA Tuberculin Share (%), by Country
  • Figure 11. North America Tuberculin Share (%), by Country
  • Figure 12. Global Tuberculin share by Players 2023 (%)
  • Figure 13. Global Tuberculin share by Players (Top 3) 2023(%)
  • Figure 14. Global Tuberculin share by Players (Top 5) 2023(%)
  • Figure 15. BCG Matrix for key Companies
  • Figure 16. Sanofi Pasteur (France) Revenue, Net Income and Gross profit
  • Figure 17. Sanofi Pasteur (France) Revenue: by Geography 2023
  • Figure 18. Zoetis (United States) Revenue, Net Income and Gross profit
  • Figure 19. Zoetis (United States) Revenue: by Geography 2023
  • Figure 20. Par Sterile (United States) Revenue, Net Income and Gross profit
  • Figure 21. Par Sterile (United States) Revenue: by Geography 2023
  • Figure 22. Japan BCG (Japan) Revenue, Net Income and Gross profit
  • Figure 23. Japan BCG (Japan) Revenue: by Geography 2023
  • Figure 24. Thermo Fisher (United States) Revenue, Net Income and Gross profit
  • Figure 25. Thermo Fisher (United States) Revenue: by Geography 2023
  • Figure 26. CNBG (China) Revenue, Net Income and Gross profit
  • Figure 27. CNBG (China) Revenue: by Geography 2023
  • Figure 28. Chirana T. Injecta (Belarus) Revenue, Net Income and Gross profit
  • Figure 29. Chirana T. Injecta (Belarus) Revenue: by Geography 2023
  • Figure 30. Arkray (Poland) Revenue, Net Income and Gross profit
  • Figure 31. Arkray (Poland) Revenue: by Geography 2023
  • Figure 32. Merck& Co. Inc.(United States) Revenue, Net Income and Gross profit
  • Figure 33. Merck& Co. Inc.(United States) Revenue: by Geography 2023
  • Figure 34. Abbott (United States) Revenue, Net Income and Gross profit
  • Figure 35. Abbott (United States) Revenue: by Geography 2023
  • Figure 36. Global Tuberculin: by Type USD Million (2025-2030)
  • Figure 37. Global Tuberculin: by Application USD Million (2025-2030)
  • Figure 38. Global Tuberculin: by Therapy USD Million (2025-2030)
  • Figure 39. South America Tuberculin Share (%), by Country
  • Figure 40. Asia Pacific Tuberculin Share (%), by Country
  • Figure 41. Europe Tuberculin Share (%), by Country
  • Figure 42. MEA Tuberculin Share (%), by Country
  • Figure 43. North America Tuberculin Share (%), by Country
List of companies from research coverage that are profiled in the study
  • Sanofi Pasteur (France)
  • Zoetis (United States)
  • Par Sterile (United States)
  • Japan BCG (Japan)
  • Thermo Fisher (United States)
  • CNBG (China)
  • Chirana T. Injecta (Belarus)
  • Arkray (Poland)
  • Merck& Co. Inc.(United States)
  • Abbott (United States)
Additional players considered in the study are as follows:
Qiagen (Germany) , BioMerieux (France) , Roche Diagnostic (Switzerland) , Becton dickinson (United States)
Select User Access Type

Key Highlights of Report


Mar 2024 170 Pages 52 Tables Base Year: 2023 Coverage: 15+ Companies; 18 Countries

Request Sample Pages

Budget constraints? Get in touch with us for special pricing


Check Discount Now
Global Tuberculin Quantitative research analysis
Global Tuberculin Qualitative Industry Analysis
DOWNLOAD SAMPLE PDF

Talk to Our Experts

Want to Customize Study?


"We employ Market statistics, Industry benchmarking, Patent analysis, and Technological Insights to derive requirements and provide customize scope of work."

Make an Enquiry Now

Frequently Asked Questions (FAQ):

Tuberculin Market is heading robustly to achieve a new growth cycle.
The Concentration Rate of Global Tuberculin market is dominated by Global Players and may generate healthy valuation by 2030.
  • Spreading Awareness about the Tuberculin
  • Government Initiatives on the Drugs Related to Tuberculosis
dominated the Tuberculin market. This is attributable to growing trend of "Increasing Expenditure on Health Care in Developing Countries "

Know More About Global Tuberculin Report?

Have a Query? Click Here

Other Related Reports

Homeopathy Comprehensive Study by Type (Tincture, Dilutions, Biochemics, Ointments, Tablets), Application (Respiratory, Neurology, Immunology, Gastroenterology, Dermatology, Others), Treatment (Auto-...
$ 3650
Medical Lab Software Comprehensive Study by Application (PC Terminal, Mobile Terminal), End users (Health Care, Medical Lab, Others), Services (MEDICAL LABORATORY MANAGEMENT, REPORTS, BILLING, TEST R...
$ 3450
Professional Dental Care Comprehensive Study by Type (Toothpastes, Toothbrushes, Mouthwashes/Rinses, Dental Accessories/Ancillaries, Denture Products), Application (Hospital, Clinic, Other) Players a...
$ 3500
Veterinary Pain Management Comprehensive Study by Type (Drugs {NSAIDs, Opiods}, Devices {Laser, Electromagnetic}), Application (Joint Pain {Osteoarthritis, Musculoskeletal Disorders}, Postoperative P...
$ 3650
Adult Knee Sleeve Comprehensive Study by Type (Strength Knee Sleeves, Lifting Knee Sleeves), Application (Cathletes, Old Man, The Injured Knee) Players and Region - Global Market Outlook to 2027
$ 3500
Healthcare Fraud Detection Comprehensive Study by Type (Descriptive Analytics, Predictive Analytics, Prescriptive Analytics), Application (Insurance Claims Review, Payment Integrity, Other), Componen...
$ 3800